Antiproteases as therapeutics to target inflammation in cystic fibrosis

Open Respiratory Medicine Journal

Volumn 4, Issue , 2010, Pages 20-31

  Quinn, Derek J ^a   Weldon, Sinéad ^a   Taggart, Clifford C ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

Bacteria; Macrophage; Neutrophil; Protease inhibitors; Proteases

Indexed keywords

ADAM PROTEIN; ALPHA 1 ANTITRYPSIN; BACTERIAL ENZYME; CATHEPSIN B; CATHEPSIN G; CYSTATIN; DX 890; ELAFIN; LEUKOCYTE ELASTASE; MATRIX METALLOPROTEINASE; MYELOBLASTIN; ONO 6818; PLACEBO; PROTEASOME; PROTEINASE INHIBITOR; SECRETORY LEUKOCYTE PROTEINASE INHIBITOR; SERINE PROTEINASE; UNCLASSIFIED DRUG;

AEROSOL; ALPHA 1 ANTITRYPSIN DEFICIENCY; ANTIBACTERIAL ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CYSTIC FIBROSIS; DRUG DELIVERY SYSTEM; DRUG MEGADOSE; DRUG TARGETING; HUMAN; LIVER FUNCTION TEST; LOW DRUG DOSE; LUNG DISEASE; NONHUMAN; PATHOGENESIS; PNEUMONIA; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STRUCTURE; PROTEIN SYNTHESIS; PSEUDOMONAS INFECTION; RESPIRATORY TRACT INFLAMMATION; SIDE EFFECT;

EID: 77953398632     PISSN: None     EISSN: 18743064     Source Type: Journal    
DOI: 10.2174/1874306401004020020     Document Type: Article

References (156)

1. Greally PM, Hussein MJ, Cook AJ, Sampson AP, Piper PJ, Price JF. Sputum tumour necrosis factor-alpha and leukotriene concentrations in cystic fibrosis. Arch Dis Child 1993; 68: 389-92.
2. Bonfield TL, Panuska JR, Konstan MW, et al. Inflammatory cytokines in cystic fibrosis lungs. Am J Respir Crit Care Med 1995; 152: 2111-18.
3. Strieter RM. Interleukin-8: a very important chemokine of the human airway epithelium. Am J Physiol 2002; 283: L688-L9.
4. Birrer P. Consequences of unbalanced protease in the lung: protease involvement in destruction and local defence mechanisms of the lung. Agents Actions Suppl 1993; 40: 3-12.
5. Sommerhoff CP, Nadel JA, Basbaum CB, Caughey GH. Neutrophil elastase and cathepsin G stimulate secretion from bovine airway gland serous cells. J Clin Invest 1990; 85: 682-89.
6. Breuer R, Christensen TG, Lucey EC, Bolbochan G, Stone PJ, Snider GL. Elastase causes secretory discharge in bronchi of hamsters with elastase-induced secretory cell metaplasia. Exp Lung Res 1993; 19: 273-82.
7. O'Connor CM, Gaffney K, Keane J, et al. 1-Proteinase inhibitor, elastase activity, and lung disease severity in cystic fibrosis. Am Rev Respir Dis 1993; 148: 1665-70.
8. Jacquot J, Tabary O, Le Rouzic P, Clement P. Airway epithelial cell inflammatory signaling in cystic fibrosis. Int J Biochem Cell Biol 2008; 40: 1703-15.
9. Taggart C, Coakely RJ, Greally P, Canny G, O'Neill SJ, McElvaney NG. Increased elastase release by CF neutrophils is mediated by tumor necrosis factor-alpha and interleukin-8. Am J Physiol Lung Cell Mol Physiol 2000; 278: L33-L41.
10. Coakley RJ, Taggart C, McElvaney NG, O'Neill SJ. Cytosolic pH and the inflammatory microenvironment modulate cell death in human neutrophils after phagocytosis. Blood 2002; 100: 3383-91.
11. May TB, Shinabarger D, Maharaj R, et al. Alginate synthesis by Pseudomonas aeruginosa: a key pathogenic factor in chronic pulmonary infections of cystic fibrosis patients. Clin Microbiol Rev 1991; 4: 191-206.
12. Singh PK, Schaefer AL, Paresk MR, Moninger TO, Welsh MJ, Greenberg EP. Quorum sensing signals indicate that cystic fibrosis lungs are infected with bacterial biofilms. Nature 2000; 407: 762-4.
13. Bass DA, DeChatlet LR, Burk RF, Shirley P, Szedja P. Polymorphonuclear leukocyte bactericidal activity and oxidative metabolism during glutathione peroxidase deficiency. Infect Immun 1977; 18: 78-84.
14. Doring G. The role of neutrophil elastase in chronic inflammation. Am J Respir Crit Care Med 1994; 150: S114-117.
15. Fick PA, Robins RA, Squier SU, Schoderbek WE, Russ WD. Complement activation in cystic fibrosis respiratory fluids: in vivo and in vitro generation of C5a and chemotatic activity. Pediatr Res 1986; 20: 1258-68.
16. Berger M, Soerensen RJ, Tosi MF, Dearborn DG, Doring G. Complement receptor expression on neutrophils at an inflammatory site, the Pseudomonas infected lung in cystic fibrosis. J Clin Invest 1989; 84: 1302-13.
17. Taggart CC, Greene CM, Carroll TP, O'Neill SJ, McElvaney NG. Elastolytic proteases: Inflammation resolution and dysregulation in chronic infective lung disease. Am J Respir Crit Care Med 2005; 171: 1070-6.
18. Vandivier RW, Fadok VA, Hoffmann PR, et al. Elastase-mediated phosphatidylserine receptor cleavage impairs apopotic cell clearance in cystic fibrosis and bronchiectasis. J Clin Invest 2002; 109: 661-70.
19. Walsh DE, Greene CM, Carroll TP, et al. Interleukin-8 up-regulation by neutrophil elastase is mediated by MyD88/IRAK/TRAF-6 in human bronchial epithelium. J Biol Chem 2001; 276: 35494-9.
20. Fahy JV, Schuster A, Ueki I, Boushey HA, Nadel JA. Mucus hypersecretion in bronchiestasis: the role of neutrophil proteases. Am Rev Respir Dis 1992; 146: 1430-3.
21. Ferry G, Longchampt M, Pennel L, de Nanteuil G, Canet E, Tucker GC. Activation of MMP-9 by neutrophil elastase in an in vivo model of acute lung injury. FEBS Lett 1997; 402: 111-15.
22. Itoh Y, Nagase H. Preferential inactivation of tissue inhibitor of metalloproteinases-1 that is bound to the precursor of matrix metalloproteinase 9 (progelatinase B) by human neutrophil elastase. J Biol Chem 1995; 270: 16518-21.
23. Shamamian P, Schwartz JD, Pocock BJ, et al. Activation of progelatinase A (MMP-2) by neutrophil elastase, cathepsin G, and proteinase-3: a role for inflammatory cells in tumor invasion and angiogenesis. J Cell Physiol 2001; 189: 197-206.
24. Elizur A, Cannon CL, Ferkol TW. Airway inflammation in cystic fibrosis. Chest 2008; 133: 489-95.
25. Dulon S, Cande C, Bunnett NW, Hollenberg MD, Chignard M, Pidard D. Proteinase-activated receptor-2 and human lung epithelial cells: disarming by neutrophil serine proteinases. Am J Respir Cell Mol Biol 2003; 28: 339-46.
26. Rubio F, Cooley J, Accurso FJ, Remold-O'Donnell E. Linkage of neutrophil serine proteases and decreased surfactant protein-A (SP-A) levels in inflammatory lung disease. Thorax 2004; 59: 318-23.
27. Padrines M, Wolf M, Walz A, Baggiolini M. Interleukin-8 processing by neutrophil elastase, cathepsin G and proteinase-3. FEBS Lett 1994; 352: 231-5.
28. Van den Steen PE, Proost P, Wuyts A, Van Damme J, Opdenakker G. Neutrophil gelatinase B potentiates interleukin-8 tenfold by aminoterminal processing, whereas it degrades CTAP-III, PF-4, and GRO-alpha and leaves RANTES and MCP-2 intact. Blood 2000; 96: 2673-81.
29. Witko-Sarsat V, Halbwachs-Mecarelli L, Schuster A, et al. Proteinase 3, a potent secretagogue in airways, is present in cystic fibrosis sputum. Am J Respir Cell Mol Biol 1999; 20: 729-36.
30. Duranton J, Bieth JG. Inhibition of proteinase 3 by [alpha] 1-antitrypsin in vitro predicts very fast inhibition in vivo. Am J Respir Cell Mol Biol 2003 1: 57-61.
31. Balfour-Lynn IM. The protease-antiprotease battle in the cystic fibrosis lung. J R Soc Med 1999; 92(Suppl 37): 23-30.
32. Birrer P, McElvaney N, Rüderberg A, et al. Protease-antiprotease imbalance in the lungs of children with cystic fibrosis. Am J Respir Crit Care Med 1994; 150: 207-213.
33. Suter S, Schaad UB, Tegner H, Ohlsson K, Desgrandchamps D, Waldvogel FA. Levels of free granulocyte elastase in bronchial secretions from patients with cystic fibrosis: effect of antimicrobial treatment against Pseudomonas aeruginosa. J Infect Dis 1986; 153: 902-9.
34. Suter S. Imbalance between polymorphonuclear leukocyte proteases and antiproteases in chronic pyogenic infections and its relation to the proteolysis of complement component C3. Complement 1986; 3: 1-24.
35. Ying QL, Simon SR. Kinetics of the inhibition of human leukocyte elastase by elafin, a 6-kilodalton elastase-specific inhibitor from human skin. Biochemistry 1993; 32: 1866-74.
36. Sallenave JM, Silva A. Characterization and gene sequence of the precursor of elafin, an elastase-specific inhibitor in bronchial secretions. Am J Respir Cell Mol Biol 1993; 8: 439-45.
37. Burden RE, Scott CJ. Cysteine cathepsins in pulmonary diseases. In: Taggart CC, Greene CM, Eds. Mechanisms of pulmonary innate immunity. India: Research Signpost 2008; pp. 135-56.
38. Gueders MM, Foidart JM, Noel A, Cataldo DD. Matrix metalloproteinases (MMPs) and tissue inhibitors of MMPs in the respiratory tract: potential implications in asthma and other lung diseases. Eur J Pharmacol 2006; 533: 133-44.
39. Long GL, Chandra T, Woo SL, Davie EW, Kurachi K. Complete sequence of the cDNA for human alpha 1-antitrypsin and the gene for the S variant. Biochemistry 1984; 23: 4828-37.
40. Brantly M, Nukiwa T, Crystal RG. Molecular basis of alpha-1-antitrypsin deficiency. Am J Med 1988; 84: 13-31.
41. Crystal RG, Brantly ML, Hubbard RC, Curiel DT, States DJ, Holmes MD. The alpha 1-antitrypsin gene and its mutations. Clinical consequences and strategies for therapy. Chest 1989; 95: 196-208.
42. Travis J, Salvesen GS. Human plasma proteinase inhibitors. Annu Rev Biochem 1983; 52: 655-709.
43. Mornex JF, Chytil-Weir A, Martinet Y, Courtney M, LeCocq JP, Crystal RG. Expression of the alpha-1-antitrypsin gene in mononuclear phagocytes of normal and alpha-1-antitrypsin-deficient individuals. J Clin Invest 1986; 77: 1952-61.
44. du Bois RM, Bernaudin JF, Paakko P, et al. Human neutrophils express the alpha 1-antitrypsin gene and produce alpha 1-antitrypsin. Blood 1991; 77: 2724-30.
45. Janciauskiene SM, Stevens T. Alpha1-antitrypsin, old dog, new tricks. Alpha1-antitrypsin exerts in vitro anti-inflammatory activity in human monocytes by elevating cAMP. J Biol Chem 2007; 282: 8573-82.
46. Lomas DA, Carrell RW. Serpinopathies and the conformational dementias. Nat Rev Genet 2002; 3: 759-68.
47. Whisstock J, Skinner R, Lesk AM. An atlas of serpin conformations. Trends Biochem Sci 1998; 23: 63-7.
48. Banda MJ, Rice AG, Griffin GL, Senior RM. The inhibitory complex of human alpha 1-proteinase inhibitor and human leukocyte elastase is a neutrophil chemoattractant. J Exp Med 1988; 167: 1608-15.
49. Beatty K, Bieth J, Travis J. Kinetics of association of serine proteinases with native and oxidized alpha-1-proteinase inhibitor and alpha-1-antichymotrypsin. J Biol Chem 1980; 255: 3931-4.
50. Johnson D, Travis J. The oxidative inactivation of human alpha-1-proteinase inhibitor. Further evidence for methionine at the reactive center. J Biol Chem 1979; 254: 4022-6.
51. Taggart C, Cervantes-Laurean D, Kim G, et al. Oxidation of either methionine 351 or methionine 358 in alpha 1-antitrypsin causes loss of anti-neutrophil elastase activity. J Biol Chem 2000; 275: 27258-65.
52. Griffiths SW, Cooney CL. Relationship between protein structure and methionine oxidation in recombinant human alpha 1-antitrypsin. Biochemistry 2002; 41: 6245-52.
53. Padrines M, Schneider-Pozzer M, Bieth JG. Inhibition of neutrophil elastase by alpha-1-proteinase inhibitor oxidized by activated neutrophils. Am Rev Respir Dis 1989; 139: 783-90.
54. Appelhans B, Ender B, Sachse G, Nikiforov T, Appelhans H, Ebert W. Secretion of antileucoprotease from a human lung tumor cell line. FEBS Lett 1987; 224: 14-18.
55. Franken C, Meijer CJ, Dijkman JH. Tissue distribution of antileukoprotease and lysozyme in humans. J Histochem Cytochem 1989; 37: 493-8.
56. Heinzel R, Appelhans H, Gassen G, et al. Molecular cloning and expression of cDNA for human antileukoprotease from cervix uterus. Eur J Biochem 1986; 160: 61-7.
57. Lee CH, Igarashi Y, Hohman RJ, Kaulbach H, White MV, Kaliner MA. Distribution of secretory leukoprotease inhibitor in the human nasal airway. Am Rev Respir Dis 1993; 147: 710-16.
58. Stetler G, Brewer MT, Thompson RC. Isolation and sequence of a human gene encoding a potent inhibitor of leukocyte proteases. Nucleic Acids Res 1986; 14: 7883-96.
59. Thompson RC, Ohlsson K. Isolation, properties, and complete amino acid sequence of human secretory leukocyte protease inhibitor, a potent inhibitor of leukocyte elastase. Proc Natl Acad Sci USA 1986; 83: 6692-6.
60. Clauss A, Lilja H, Lundwall A. A locus on human chromosome 20 contains several genes expressing protease inhibitor domains with homology to whey acidic protein. Biochem J 2002; 368: 233-42.
61. Weldon S, McGarry N, Taggart CC. SLPI and elafin: multifunctional components of the respiratory tract. In: Taggart CC & Greene CM, Eds. Mechanisms of pulmonary innate immunity. India: Research Signpost 2008; p. 201.
62. Bingle CD, Vyakarnam A. Novel innate immune functions of the whey acidic protein family. Trends Immunol 2008; 29: 444-53.
63. Moreau T, Baranger K, Dadé S, Dallet-Choisy S, Guyot N, Zani ML. Multifaceted roles of human elafin and secretory leukocyte proteinase inhibitor (SLPI), two serine protease inhibitors of the chelonianin family. Biochimie 2008; 90: 284-95.
64. Fitch PM, Roghanian A, Howie SE, Sallenave JM. Human neutrophil elastase inhibitors in innate and adaptive immunity. Biochem Soc Trans 2006; 34: 279-82.
65. Williams SE, Brown TI, Roghanian A, Sallenave JM. SLPI and elafin: one glove, many fingers. Clin Sci (Lond) 2006; 110: 21-35.
66. Jin FY, Nathan C, Radzioch D, Ding A. Secretory leukocyte protease inhibitor: a macrophage product induced by and antagonistic to bacterial lipopolysaccharide. Cell 1997; 88: 417-26.
67. Sallenave JM, Si-Ta Har M, Cox G, Chignard M, Gauldie J. Secretory leukocyte proteinase inhibitor is a major leukocyte elastase inhibitor in human neutrophils. J Leukoc Biol 1997; 61: 695-702.
68. Rao NV, Marshall BC, Gray BH, Hoidal JR. Interaction of secretory leukocyte protease inhibitor with proteinase-3. Am J Respir Cell Mol Biol 1993; 8: 612-16.
69. Rogan MP, Geraghty P, Greene CM, O'Neill SJ, Taggart CC, McElvaney NG. Antimicrobial proteins and polypeptides in pulmonary innate defence. Respir Res 2006; 7: 29.
70. Nakamura A, Mori Y, Hagiwara K, et al. Increased susceptibility to LPS-induced endotoxin shock in secretory leukoprotease inhibitor (SLPI)-deficient mice. J Exp Med 2003; 197: 669-74.
71. Lentsch AB, Jordan JA, Czermak BJ, et al. Inhibition of NF-kappaB activation and augmentation of IkappaBbeta by secretory leukocyte protease inhibitor during lung inflammation. Am J Pathol 1999; 154: 239-47.
72. Mulligan MS, Lentsch AB, Huber-Lang M, et al. Anti-inflammatory effects of mutant forms of secretory leukocyte protease inhibitor. Am J Pathol 2000; 156: 1033-9.
73. Taggart CC, Cryan SA, Weldon S, et al. Secretory leukocyte protease inhibitor binds to NF-{kappa}B binding sites in monocytes and inhibits p65 binding. J Exp Med 2005; 202: 1659-68.
74. Greene C, Taggart C, Lowe G, Gallagher P, McElvaney N, O'Neill S. Local impairment of anti-neutrophil elastase capacity in community acquired pneumonia. J Infect Dis 2003; 188: 769-76.
75. Taggart CC, Greene CM, McElvaney NG, O'Neill S. Secretory leucoprotease inhibitor prevents lipopolysaccharide-induced IkappaBalpha degradation without affecting phosphorylation or ubiquitination. J Biol Chem 2002; 277: 33648-53.
76. Grutter MG, Fendrich G, Huber R, Bode W. The 2.5 A X-ray crystal structure of the acid-stable proteinase inhibitor from human mucus secretions analysed in its complex with bovine alpha-chymotrypsin. EMBO J 1988; 7: 345-51.
77. Heinzel-Wieland R, Steffens GJ, Flohe L. Inhibitory characteristics and oxidant resistance of site specific variants of recombinant human antileukoproteinase (ALP). Biomed Biochim Acta 1991; 50: 677-81.
78. Taggart CC, Lowe GJ, Greene CM, et al. Cathepsin B, L, and S cleave and inactivate secretory leucoprotease inhibitor. J Biol Chem 2001; 276: 33345-52.
79. Sallenave JM, Ryle AP. Purification and characterization of elastase-specific inhibitor. Sequence homology with mucus proteinase inhibitor. Biol Chem Hoppe Seyler 1991; 372: 13-21.
80. Molhuizen HO, Alkemade HA, Zeeuwen PL, de Jongh GJ, Wieringa B, Schalkwijk J. SKALP/elafin: an elastase inhibitor from cultured human keratinocytes. Purification, cDNA sequence, and evidence for transglutaminase cross-linking. J Biol Chem 1993; 268: 12028-32.
81. Sumi Y, Inoue N, Azumi H, et al. Expression of tissue transglutaminase and elafin in human coronary artery: implication for plaque instability. Atherosclerosis 2002; 160: 31-9.
82. Mihaila A, Tremblay GM. Human alveolar macrophages express elafin and secretory leukocyte protease inhibitor. Z Naturforsch [C] 2001; 56: 291-7.
83. Zhang M, Magit D, Pardee AB, Sager R. Re-expression of elafin in 21MT2 breast carcinomas by phorbol 12-myristate 13-acetate is mediated by the Ap1 site in the elafin promoter. Cancer Res 1997; 57: 4631-6.
84. Bingle L, Tetley TD, Bingle CD. Cytokine-mediated induction of the human elafin gene in pulmonary epithelial cells is regulated by nuclear factor-kappaB. Am J Respir Cell Mol Biol 2001; 25: 84-91.
85. Ying QL, Simon SR. Kinetics of the inhibition of proteinase 3 by elafin. Am J Respir Cell Mol Biol 2001; 24: 83-9.
86. Simpson AJ, Wallace WA, Marsden ME, et al. Adenoviral augmentation of elafin protects the lung against acute injury mediated by activated neutrophils and bacterial infection. J Immunol 2001; 167: 1778-86.
87. Vachon E, Bourbonnais Y, Bingle CD, Rowe SJ, Janelle MF, Tremblay GM. Anti-inflammatory effect of pre-elafin in lipopolysaccharide-induced acute lung inflammation. Biol Chem 2002; 383: 1249-56.
88. Guyot N, Butler MW, McNally P, et al. Elafin, an elastase-specific inhibitor, is cleaved by its cognate enzyme neutrophil elastase in sputum from individuals with cystic fibrosis. J Biol Chem 2008; 283: 32377-85.
89. Wright JL, Farmer SG, Churg A. Synthetic serine elastase inhibitor reduces cigarette smoke-induced emphysema in guinea pigs. Am J Respir Crit Care Med 2002; 166: 954-60.
90. Shinguh Y, Yamazaki A, Inamura N, et al. Biochemical and pharmacological characterization of FR134043, a novel elastase inhibitor. Eur J Pharmacol 1998; 345: 299-308.
91. Williams JC, Stein RL, Giles RE, Krell RD. Biochemistry and pharmacology of ICI 200, 880, a synthetic peptide inhibitor of human neutrophil elastase. Ann N Y Acad Sci 1991; 624: 230-43.
92. Tarjan E, Peto L, Appel J, Tolnay P. Protective effect of specific elastase inhibitor in experimental pulmonary emphysema. Schweiz Med Wochenschr 1984; 114: 918-20.
93. Wewers MD, Casolaro MA, Crystal RG. Comparison of alpha-1-antitrypsin levels and antineutrophil elastase capacity of blood and lung in a patient with the alpha-1-antitrypsin phenotype null-null before and during alpha-1-antitrypsin augmentation therapy. Am Rev Respir Dis 1987; 135: 539-43.
94. Hubbard RC, Sellers S, Czerski D, Stephens L, Crystal RG. Biochemical efficacy and safety of monthly augmentation therapy for alpha 1-antitrypsin deficiency. JAMA 1988; 260: 1259-64.
95. Moore JE, Shaw A, Millar BC, et al. Reduction in neutrophil elastase concentration by recombinant alphal-antitrypsin (recAAT) does not alter bacterial loading in the sputum of cystic fibrosis patients. Br J Biomed Sci 2004; 61(3): 146-7.
96. Martin SL, Downey D, Bilton D, Keogan MT, Edgar J, Elborn JS. Safety and efficacy of recombinant alpha(1)-antitrypsin therapy in cystic fibrosis. Pediatr Pulmonol 2006; 2: 177-83.
97. Cantin AM, Berthiaume Y, Cloutier D, Martel M. Prolastin aerosol therapy and sputum taurine in cystic fibrosis. Clin Invest Med 2006; 4: 201-7.
98. Griese M, Latzin P, Kappler M, et al. alpha1-Antitrypsin inhalation reduces airway inflammation in cystic fibrosis patients. Eur Respir J 2007; 2: 240-50.
99. Brand P, Schulte M, Wencker M, et al. Lung deposition of inhaled alpha1-proteinase inhibitor in cystic fibrosis and alpha1-antitrypsin deficiency. Eur Respir J 2009; 34(2): 354-60.
100. Ferkol T, Cohn LA, Phillips TE, Smith A, Davis PB. Targeted delivery of antiprotease to the epithelial surface of human tracheal xenografts. Am J Respir Crit Care Med 2003; 167: 1374-9.
101. Cereijido M, Ponce A, Gonzalez-Marical J. Tight junctions and apical basolateral polarity. J Membr Biol 1989; 110: 1-9.
102. McElvaney NG, Nakamura H, Birrer P, et al. Modulation of airway inflammation in cystic fibrosis. In vivo suppression of interleukin-8 levels on the respiratory epithelial surface by aerosolization of recombinant secretory leukoprotease inhibitor. J Clin Invest 1992; 90: 1296-301.
103. McElvaney NG, Doujaiji B, Moan MJ, Burnham MR, Wu MC, Crystal RG. Pharmacokinetics of recombinant secretory leukoprotease inhibitor aerosolized to normals and individuals with cystic fibrosis. Am Rev Respir Dis 1993; 148: 1056-60.
104. Gillissen A, Birrer P, McElvaney NG, et al. Recombinant secretory leukoprotease inhibitor augments glutathione levels in lung epithelial lining fluid. J Appl Physiol 1993; 75: 825-32.
105. Proteo Biotech AG. Available from: www.proteo.de/framesets/r-and-d.php?lang=en [Accessed: October 26, 2009].
106. Grimbert D, Vecellio L, Delépine P, et al. Characteristics of EPI-hNE4 aerosol: a new elastase inhibitor for treatment of cystic fibrosis. J Aerosol Med 2003; 16(2): 121-9.
107. Attucci S, Gauthier A, Korkmaz B, et al. EPI-hNE4, a proteolysis-resistant inhibitor of human neutrophil elastase and potential anti-inflammatory drug for treating cystic fibrosis. J Pharmacol Exp Ther 2006; 318(2): 803-9.
108. Ono Pharmaceutical Co., Ltd. Available from: http://www.ono.co.jp/eng/default.htm [Accessed: October 26, 2009].
109. Wolters PJ, Chapman HA. Importance of lysosomal cysteine proteases in lung disease. Respir Res 2001; 1: 170-7.
110. Bühling F, Waldburg N, Reisenauer A, Heimburg A, Golpon H, Welte T. Lysosomal cysteine proteases in the lung: role in protein processing and immunoregulation. Eur Respir J 2004; 23: 620-8.
111. Chapman HA Jr, Shi GP. Protease injury in the development of COPD: Thomas A. Neff Lecture. Chest 2000; 117: 295S-99S.
112. Bühling F, Gerber A, Häckel C, et al. Expression of cathepsin K in lung epithelial cells. Am J Respir Cell Mol Biol 1999; 20: 612-19.
113. Shi GP, Munger JS, Meara JP, Rich DH, Chapman HA. Molecular cloning and expression of human alveolar macrophage cathepsin S, an elastinolytic cysteine protease. J Biol Chem 1992; 267: 7258-62.
114. Brasch F, Ten Brinke A, Johnen G, et al. Involvement of cathepsin H in the processing of the hydrophobic surfactant-associated protein C in type II pneumocytes. Am J Respir Cell Mol Biol 2002; 26: 659-70.
115. Kirschke H, Wiederanders B. Cathepsin S and related lysosomal endopeptidases. Methods Enzymol 1994; 244: 500-11.
116. Wolters PJ, Raymond WW, Blount JL, Caughey GH. Regulated expression, processing, and secretion of dog mast cell dipeptidyl peptidase I. J Biol Chem 1998; 273: 15514-20.
117. Tate S, MacGregor G, Davis M, Innes JA, Greening AP. Airways in cystic fibrosis are acidified: detection by exhaled breath condensate. Thorax 2002; 57: 926-9.
118. Geraghty P, Rogan MP, Greene CM, et al. Neutrophil elastase up-regulates cathepsin B and matrix metalloprotease-2 expression. J Immunol 2007; 178: 5871-8.
119. Burnett D, Abrahamson M, Devalia JL, Sapsford RJ, Davies RJ, Buttle DJ. Synthesis and secretion of procathepsin B and cystatin C by human bronchial epithelial cells in vitro: modulation of cathepsin B activity by neutrophil elastase. Arch Biochem. Biophys 1995; 317: 305-10.
120. Taggart CC, Greene CM, Smith SG, et al. Inactivation of human -defensins 2 and 3 by elastolytic cathepsins. J Immunol 2003; 171: 931-7.
121. Rogan MP, Taggart CC, Greene CM, Murphy PG, O'Neill SJ, McElvaney NG. Loss of microbicidal activity and increased formation of biofilm due to decreased lactoferrin activity in patients with cystic fibrosis. J Infect Dis 2004; 190: 1245-53.
122. László A, Sohár I, Gyurkovits K. Activity of the lysosomal cysteine proteinases (cathepsin B,H,L) and a metalloproteinase (MMP-7-ase) in the serum of cystic fibrosis homozygous children. Acta Paediatr Hung 1987; 28: 175-8.
123. McGuire MJ, Lipsky PE, Thiele DL. Generation of active myeloid and lymphoid granule serine proteases requires processing by the granule thiol protease dipeptidyl peptidase I. J Biol Chem 1993; 268: 2458-67.
124. Murakami M, Karnik SS, Husain A. Human prochymase activation. A novel role for heparin in zymogen processing. J Biol Chem 1995; 270: 2218-23.
125. Pham CT, Ley TJ. Dipeptidyl peptidase I is required for the processing and activation of granzymes A and B in vivo. Proc Natl Acad Sci USA 1999; 96: 8627-32.
126. Johnson DA, Barrett AJ, Mason RW. Cathepsin L inactivates alpha 1-proteinase inhibitor by cleavage in the reactive site region. J Biol Chem 1986; 261: 14748-51.
127. Abrahamson M, Buttle DJ, Mason RW, et al. Regulation of cystatin C activity by serine proteinases. Biomed Biochim Acta 1991; 50: 587-93.
128. Vasiljeva O, Reinheckel T, Peters C, Turk D, Turk V, Turk B. Emerging roles of cysteine cathepsins in disease and their potential as drug targets. Curr Pharm Des 2007; 13: 387-40.
129. Sternlicht MD, Werb Z. How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol 2001; 17: 463-516.
130. Parks WC, Wilson CL, Lopez-Boado YS. Matrix metalloprotein-ases as modulators of inflammation and innate immunity. Nat Rev Immunol 2004; 4: 617-29.
131. Peterson-Carmichael SL, Harris WT, Goel R, et al. Association of lower airway inflammation with physiologic findings in young children with cystic fibrosis. Pediatr Pulmonol 2009; 44: 503-11.
132. Ratjen F, Hartog CM, Paul K, Wermelt J, Braun J. Matrix metalloproteases in BAL fluid of patients with cystic fibrosis and their modulation by treatment with dornase alpha. Thorax 2002; 57: 930-4.
133. Hilliard TN, Regamey N, Shute JK, et al. Airway remodelling in children with cystic fibrosis. Thorax 2007; 62: 1074-80.
134. Gaggar A, Li Y, Weathington N, et al. Matrix metalloprotease-9 dysregulation in lower airway secretions of cystic fibrosis patients. Am J Physiol Lung Cell Mol Physiol 2007; 293: L96-L104.
135. Sagel SD, Kapsner RK, Osberg I. Induced sputum matrix metalloproteinase-9 correlates with lung function and airway inflammation in children with cystic fibrosis. Pediatr Pulmonol 2005; 39: 224-32.
136. Ferry G, Lonchampt M, Pennel L, de Nanteuil G, Canet E, Tucker GC. Activation of MMP-9 by neutrophil elastase in an in vivo model of acute lung injury. FEBS Lett 1997; 402: 111-15.
137. Manicone AM, McGuire JK. Matrix metalloproteinases as modulators of inflammation. Semin Cell Dev Biol 2008; 19: 34-41.
138. Desrochers PE, Jeffrey JJ, Weiss SJ. Interstitial collagenase (matrix metalloproteinase-1) expresses serpinase activity. J Clin Invest 1991; 87: 2258-65.
139. Zhang Z, Winyard PG, Chidwick K, et al. Proteolysis of human native and oxidised alpha 1-proteinase inhibitor by matrilysin and stromelysin. Biochim Biophys Acta 1994; 1199: 224-8.
140. Michaelis J, Vissers MC, Winterbourn CC. Cleavage of alpha 1-antitrypsin by human neutrophil collagenase. Matrix Suppl 1992; 1: 80-1.
141. Liu Z, Zhou X, Shapiro SD, et al. The serpin alpha1-proteinase inhibitor is a critical substrate for gelatinase B/MMP-9 S. Cell 2000; 102: 647-55.
142. Shapiro SD, Goldstein NM, Houghton AM, Kobayashi DK, Kelley D, Belaaouaj A. Neutrophil elastase contributes to cigarette smoke-induced emphysema in mice. Am J Pathol 2003; 163: 2329-35.
143. Ramadas RA, Wu L, LeVine AM. Surfactant protein A enhances production of secretory leukoprotease inhibitor and protects it from cleavage by matrix metalloproteinases. J Immunol 2009; 182: 1560-7.
144. Henry MT, McMahon K, Costello C, Fitzgerald MX, O'Connor CM. Secretory leukocyte proteinase inhibitor and elafin are resistant to degradation by MMP-8. Exp Lung Res 2002; 28: 85-97.
145. Dijkstra A, Postma DS, Noordhoek JA, et al. Expression of ADAMs (a disintegrin and metalloprotease) in the human lung. Virchows Arch 2009; 454: 441-9.
146. Shao MX, Nadel JA. Neutrophil elastase induces MUC5AC mucin production in human airway epithelial cells via a cascade involving protein kinase C, reactive oxygen species, and TNF-alpha-converting enzyme. J Immunol 2005; 175: 4009-16.
147. Thathiah A, Blobel CP, Carson DD. Tumor necrosis factor-alpha converting enzyme/ADAM 17 mediates MUC1 shedding. J Biol Chem 2003; 278: 3386-94.
148. Thathiah A, Carson DD. MT1-MMP mediates MUC1 shedding independently of TACE/ADAM17. Biochem J 2004; 362: 363-73.
149. Lillehoj EP, Hyun SW, Kim BT, et al. Muc1 mucins on the cell surface are adhesion sites for Pseudomonas aeruginosa. Am J Physiol Lung Cell Mol Physiol 2001; 280: L181-L187.
150. Vij N, Fang S, Zeitlin PL. Selective inhibition of endoplasmic reticulum-associated degradation rescues F508-cystic fibrosis transmembrane regulator and suppresses interleukin-8 levels. J Biol Chem 2006; 281: 17369-78.
151. Ward CL, Omura S, Kopito RR. Degradation of CFTR by the ubiquitin-proteasome pathway. Cell 1995; 83: 121-7.
152. Mitchell BS. A phase 2 study of bortezomib in relapsed refractory myeloma. N Eng J Med 2003; 348: 2597-8.
153. Travis J, Potempa J. Bacterial proteinases as targets for the development of second-generation antibiotics. Biochimica Biophysica Acta 2000; 1477: 35-50.
154. Kamath S, Kapatral V, Chakrabarty AM. Cellular function of elastase in Pseudomonas aeruginosa: role in the cleavage of nucleoside disphosphate kinase and in alginate synthesis. Mol Microbiol 1998; 30: 933-41.
155. Leduc D, Beaufort N, de Bentzmann S, et al. The Pseudomonas aeruginosa LasB metalloproteinase regulates the human urokinase-type plasminogen activator receptor through domain-specific endoproteolysis. Infect Immun 2007; 75(8): 3848-58.
156. Govan JRW, Deretic V. Microbial pathogenesis in cystic fibrosis: mucoid Pseudomonas aeruginosa and Burkholderia cepacia. Microbiol Rev 1996; 660: 539-74.